Trial · NCT01202877

Adverse events171

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 171

Type	Event	Organ system	Group	Affected	At risk	Events
other	Anemia	Blood and lymphatic system disorders	Phase I: 5-azacytidine + PKC412 25 mg	6	6	6
other	Anemia	Blood and lymphatic system disorders	Phase I: 5-azacytidine + PKC412 50 mg	8	8	8
other	Anemia	Blood and lymphatic system disorders	Phase II: 5-azacytidine + PKC412	40	40	40
other	Acute renal failure	Renal and urinary disorders	Phase I: 5-azacytidine + PKC412 25 mg	0	6	0
other	Acute renal failure	Renal and urinary disorders	Phase I: 5-azacytidine + PKC412 50 mg	1	8	1
other	Acute renal failure	Renal and urinary disorders	Phase II: 5-azacytidine + PKC412	3	40	3
other	Hemorrhage/Bleeding	Blood and lymphatic system disorders	Phase I: 5-azacytidine + PKC412 25 mg	0	6	0
other	Hemorrhage/Bleeding	Blood and lymphatic system disorders	Phase I: 5-azacytidine + PKC412 50 mg	0	8	0
other	Hemorrhage/Bleeding	Blood and lymphatic system disorders	Phase II: 5-azacytidine + PKC412	8	40	8
other	Constipation	Gastrointestinal disorders	Phase I: 5-azacytidine + PKC412 25 mg	1	6	1
other	Constipation	Gastrointestinal disorders	Phase I: 5-azacytidine + PKC412 50 mg	1	8	1
other	Constipation	Gastrointestinal disorders	Phase II: 5-azacytidine + PKC412	6	40	6
other	Fatigue	General disorders	Phase I: 5-azacytidine + PKC412 25 mg	2	6	2
other	Fatigue	General disorders	Phase I: 5-azacytidine + PKC412 50 mg	1	8	1
other	Fatigue	General disorders	Phase II: 5-azacytidine + PKC412	0	40	0
other	Hyperbilirubinemia	Investigations	Phase I: 5-azacytidine + PKC412 25 mg	2	6	2
other	Hyperbilirubinemia	Investigations	Phase I: 5-azacytidine + PKC412 50 mg	0	8	0
other	Hyperbilirubinemia	Investigations	Phase II: 5-azacytidine + PKC412	7	40	7
other	Hyperglycemia	Metabolism and nutrition disorders	Phase I: 5-azacytidine + PKC412 25 mg	0	6	0
other	Hyperglycemia	Metabolism and nutrition disorders	Phase I: 5-azacytidine + PKC412 50 mg	0	8	0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01202877/events

API reference For AI assistants

Adverse events171

Sources 3

Read this list from software.